Vnitr Lek 2009, 55(9):719-723

Hypertension combination therapy with rennin-angiotenzin system blockers

M. Souček
II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc.

Target blood pressure levels are not being achieved with the current hypertension treatment. Monotherapy that normalizes BP in about 20% of patients does not provide sufficient control to reach this goal and thus combination therapy is required. Results from recent clinical studies showed that a combination of an angiotenzin-converting enzyme inhibitor (ACEi) with a calcium channel blocker (CCB) provide better results and reduced incidence of cardiovascular events than a combination of a diuretic with an ACE inhibitor. Combination therapy based on rennin-angiotenzin system blockade: ACEi with a CCB, ACEi with a diuretic or angiotenzin receptor blocker (AT1) with a diuretic as a first-line treatment of the stage 2 hypertension might lead to significantly better control of blood pressure than monotherapy.

Keywords: combination of hypertensives; angiotenzin-converting enzyme inhibitor; angiotenzin receptor blocker; diuretics; calcium channel blockers

Received: July 14, 2009; Published: September 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Souček M. Hypertension combination therapy with rennin-angiotenzin system blockers. Vnitr Lek. 2009;55(9):719-723.
Download citation

References

  1. Patel A and ADVANCE Collaborating Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular aoutcomes in patients type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829-840. Go to original source... Go to PubMed...
  2. Beckett NS, Peters R, Fletcher AE et al. for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898. Go to original source... Go to PubMed...
  3. Jamerson K, Bakris GL, Dahlöf B et al. Exceptional early blood pressure control rates: The ACCOPMLISH trial. Blood Pressure 2007; 16: 80-86. Go to original source... Go to PubMed...
  4. Weir MR, Neutel JM, Bhaumik A et al. The efficacy and safety of initial use of irbesartan/HCTZ fixed dose combination in hypertensive patients with a without high cardiovascular risk. J Clin Hypertens 2007; 9 (12 Suppl): 23-30. Go to original source... Go to PubMed...
  5. Neutel JM, Franklin SS, Lapuerta P et al. A comparison of the efficacy and safety of irbesartan/H CTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens 2007; 22: 266-274. Go to original source... Go to PubMed...
  6. Pepine CJ, Handberg EM, Cooper-Dehoff RM et al for the INVEST investigators. A calcium antagonist versus a noncalcium antagonist hypertension treatment strategy for patients with corononary heart disease: The International Verapamil-Trandolapril Study (INVEST): A randomised controlled trial. JAMA 2003; 290: 2805-2816. Go to original source... Go to PubMed...
  7. Nadar S, Lim HS, Beevers DG et al. Lipid lowering in hypertension and heart protection: observation from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study. J Hum Hypertens 2002; 16: 815-817. Go to original source... Go to PubMed...
  8. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788. Go to original source... Go to PubMed...
  9. Weber MA. New opportunities in cardio-vascular patient management: A survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am J Cardiol 2007; 100 (3A): 45J-52J. Go to original source... Go to PubMed...
  10. Doulton TWR, He FJ, MacGregor GA. Systemic review of combined angiotensin-converting enzyme inhibitor and angiotensin receptor blockade in hypertension. Hypertension 2005; 45: 880-886. Go to original source... Go to PubMed...
  11. Sleight P. The ONTARGET/TRANSCEND trial program: baseline data. Acta Diabetol 2005; 42 (Suppl 1): S50-S56. Go to original source... Go to PubMed...
  12. Fischer ND, Hollenberg NK. Renin inhibition: What are the therapeutic opportunities? J Am Soc Nephrol 2005; 16: 592-599. Go to original source... Go to PubMed...
  13. Oparil S, Yarows SA, Patel S et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet 2007; 370: 221-229. Go to original source... Go to PubMed...
  14. Messerli FH, Bell DSH, Fonesca V et al. Body weight changes with beta blocker use: results from GEMINI. Am J Med 2007; 120: 610-615. Go to original source... Go to PubMed...
  15. Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227-2236. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.